AboutADVA Biotechnology is an Israeli based private company focused on developing enabling technologies for cell therapy manufacturing.
The company was established in 2016 by a group of cell therapy and engineering experts with vast experience in cell therapy cGMP manufacturing and development and a vision of enabling lifesaving cell therapies to patients worldwide.
The unique blend of talent and expertise combined with the supporting and innovative ecosystem in Israel with a mission to enable lifesaving therapies to patients gives the company its core advantage.
Adva company is proud to announce the accomplishment of its first goal of developing an automated, controlled and simple to use platform for autologous cell manufacturing initially for immune cell therapies (ICT) such as Chimeric Antigen Receptor (CAR T), T Cell Receptor (TCR), Natural Killer cells (NK) and T infiltrating Lymphocytes (TIL’s) called the ADVA X3.
The automated platform is designed to allow autologous manufacturing of additional types of cells with a change in the disposable chamber allowing efficiency and flexibility with a long pipeline of products.